Irritable Bowel Syndrome - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 129 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Irritable Bowel Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H2 2015', provides an overview of the Irritable Bowel Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Irritable Bowel Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Irritable Bowel Syndrome - Overview 10
Irritable Bowel Syndrome - Therapeutics under Development by Companies 11
Irritable Bowel Syndrome - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Irritable Bowel Syndrome - Products under Development by Companies 16
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 18
4D Pharma Plc 18
A. Menarini Industrie Farmaceutiche Riunite Srl 19
Alba Therapeutics Corporation 20
Alfa Wassermann S.p.A 21
Allergan Plc 22
Ardelyx, Inc. 23
Astellas Pharma Inc. 24
CJ HealthCare Corp. 25
Dong-A Socio Group 26
Enterome Bioscience SA 27
ImmusanT, Inc. 28
Ironwood Pharmaceuticals, Inc. 29
Ono Pharmaceutical Co., Ltd. 30
Pfizer Inc. 31
Protagonist Therapeutics Inc. 32
RaQualia Pharma Inc. 33
SK Biopharmaceuticals Co., Ltd. 34
SK Chemicals Co., Ltd. 35
Sumitomo Dainippon Pharma Co., Ltd. 36
Synergy Pharmaceuticals, Inc. 37
Synthetic Biologics, Inc. 38
Takeda Pharmaceutical Company Limited 39
Yuhan Corporation 40
Irritable Bowel Syndrome - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
ASP-1017 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASP-7147 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Blautix - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
crofelemer DR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DA-6886 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DSP-6952 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
EB-120 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eluxadoline - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ibodutant - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
larazotide acetate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
linaclotide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Nexvax-2 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ONO-2952 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PBF-677 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
plecanatide - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pregabalin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
relenopride hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
rifaximin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
RQ-00202730 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RQ-00310941 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SKI-3246 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to inhibit IBAT for Chronic Constipation and Irritable Bowel Syndrome - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
solabegron hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SYN-010 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TAK-480 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
tenapanor hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
YH-12852 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Irritable Bowel Syndrome - Recent Pipeline Updates 89
Irritable Bowel Syndrome - Dormant Projects 116
Irritable Bowel Syndrome - Discontinued Products 119
Irritable Bowel Syndrome - Product Development Milestones 120
Featured News & Press Releases 120
Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 120
Dec 07, 2015: Synthetic Biologics to Webcast Microbiome Clinical Program Seminar 121
Nov 30, 2015: Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan 121
Nov 24, 2015: Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation 122
Nov 19, 2015: Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City 123
Nov 02, 2015: Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation 123
Oct 28, 2015: Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrology's Kidney Week Meeting 2015 124
Oct 20, 2015: Synthetic Biologics' Novel Irritable Bowel Syndrome with Constipation Program Featured in American College of Gastroenterology Poster 125
Oct 19, 2015: Allergan to Present New Data for VIBERZI (eluxadoline) at the American College of Gastroenterology 2015 Annual Scientific Meeting 126
Oct 13, 2015: Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2015 10
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Development by Companies, H2 2015 (Contd..1) 17
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2015 18
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 19
Irritable Bowel Syndrome - Pipeline by Alba Therapeutics Corporation, H2 2015 20
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2015 21
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H2 2015 22
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H2 2015 23
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2015 24
Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H2 2015 25
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Group, H2 2015 26
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2015 27
Irritable Bowel Syndrome - Pipeline by ImmusanT, Inc., H2 2015 28
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015 29
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 30
Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H2 2015 31
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H2 2015 32
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2015 33
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 34
Irritable Bowel Syndrome - Pipeline by SK Chemicals Co., Ltd., H2 2015 35
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 36
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2015 37
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2015 38
Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 39
Irritable Bowel Syndrome - Pipeline by Yuhan Corporation, H2 2015 40
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 45
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 89
Irritable Bowel Syndrome - Dormant Projects, H2 2015 116
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H2 2015 117
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H2 2015 118
Irritable Bowel Syndrome - Discontinued Products, H2 2015 119